Test bank for focus on nursing pharmacology 7th edition by ka
b b b b b b b b b b
rch all chapters
b b
Advanced Health Assessment (Walden University)
b b b b
, TestbBank bfor bFocus bOnbNursingbPharmacologyb7thbEditio
n
Chapterb 1:b Introduction b to b Drugs
CognitivebLevel:b Applicationb Diffic
ulty:b Moderate
Integrated b Process:b Nursingb process
1.A b nurseb workingb inb radiologyb administersb iodineb tobabpatient bwhobisb havingb ab comput
erized b axialb tomographyb (CAT)b scan.bAbnurseb workingb onb anb oncologyb unit b administ
ersb chemotherapyb tob patientsb whob havebcancer.b Atb thebPublicb Healthb Department,bab n
urseb administersb ab measles-mumps-rubellab (MMR)b vaccineb tob ab 14-b month-
old b child b asb ab routineb immunization.b Whichb branchb of b pharmacologyb best b describesb t
heb actionsb of b allb threeb nurses?
A) Pharmacoeconomics
B) Pharmacotherapeutics
C) Pharmacodynamics
D) Pharmacokinetics
Ans: B
Response:
Pharmacologyb isb theb studyb of bthebbiologicb effectsbofb chemicals.b Nursesb areb involved b wi
thb clinicalb pharmacologyb orb pharmacotherapeutics,b whichb isb ab branchb of b pharmacology
b that b dealsb withb theb usesbof bdrugsb tobtreat,b prevent,bandbdiagnoseb disease.b Theb nurseb wor
kingb inb radiologyb isb administeringb ab drugb tob helpb diagnoseb ab disease.bTheb nurseb workin
gb onb anb oncologyb unit bisb administeringb ab drugb tob helpbtreat babdisease.b Pharmacoeconomi
csb includesb anyb costsb involved b inb drugb therapy.
Pharmacodynamicsb involvesb howb ab drugbaffectsbtheb body,b and b pharmacokineticsb isb ho
wb theb bodyb actsb onb theb drug.
CognitivebLevel:b Comprehensionb Di
fficulty:b Easy
Integrated b Process:b Nursingb process
2.A b physicianb hasb ordered b intramuscularb injectionsb of b morphine,b ab narcotic,b everyb 4b hour
sb asb needed bforbpainb forb abmotorbvehicleb accident bvictim.bTheb nurseb isb awareb that bthereb is
b ab highb abuseb potentialb forb thisb drug;b therefore,b morphineb isb categorized b asb a:
A) Scheduleb I b drug
B) Scheduleb II b drug
C) Scheduleb III b drug
D) Scheduleb IVb drug
Ans: B
Response:
Narcoticsb suchb asb morphineb areb considered b scheduleb IIb drugsbbecauseb of bthebhighb abuse
b potentialb withb severeb dependenceb liability.b Scheduleb Ibdrugsb haveb highb abusebpotentialb
and b nob accepted bmedicalb use.b Scheduleb III bdrugsb haveb ab lesserb abuseb potentialb thanb sch
eduleb II b drugsbandb anbacceptedbmedicalb use.bScheduleb IVbdrugsbhaveb low babuseb potentia
lb and b limited b dependenceb liability.
CognitivebLevel:b Comprehensionb
Difficulty:b Easy
Integrated b Process:b Communicationb and b documentation
3.A bnurseb workingb forb abdrugb companybisb involved binb phaseb III b drugb evaluationb studies.b
Whichb of b theb followingb might b theb nurseb bebresponsibleb forb duringb thisb stagebof bdrugbde
velopment?
Pageb 1
, TestbBank bfor bFocus bOnbNursingbPharmacologyb7thbEditio
n
Chapterb 1:b Introduction b to b Drugs
A) Workingbwithb animalsb whob areb givenb experimentalb drugs
B) Monitoringb drugb effectsbinbpatientsbwhobarebselected btobparticipateb inbabstudy,bwh
ob haveb theb diseaseb that b theb drugb isb meant b tob treat
C) Collectingb recordsb of b symptomsb that b participantsb experienceb whileb takingb ab dru
gb and b determiningb whetherb theybareb caused bbybthebdiseaseb orb thebdrugb Informing
D) b healthy,b youngb volunteerbparticipantsb ofbpossibleb risksb that bcouldb occurb fromb tak
ingb anb experimentalb drug
Ans: C
Response:
Phaseb III b studiesb involveb useb ofb abdrugb inb ab vast b clinicalb market b whereb patientsb areb aske
d b tob record banybsymptomsb theybexperienceb whileb takingb thebdrugs.b Nursesb maybbeb respo
nsibleb forb helpingb collect b and b analyzeb theb informationb tobbeb sharedb withb theb Food b and b
Drugb Administrationb (FDA).b Usebof banimalsb inb drugb testingb isb donebinb theb preclinicalb tr
ials.b Ab select b groupb of b patientsb whob areb involved binb phaseb II b studiesb participateb inb studi
esb whereb theb participantsb haveb thebdiseaseb theb drugb isb intendedbtobtreat.b Theseb patientsba
reb monitored b closelyb forb drugb effects.bPhaseb Ib studiesb involveb healthyb humanb volunteer
sb whob areb usuallyb paid b forb theirb participation.b Nursesb mayb observeb forb adverseb effectsb a
nd b toxicity.
CognitivebLevel:b Comprehensionb Di
fficulty:b Moderate
Integrated b Process:b Nursingb Process
4. Whichb of b theb followingb conceptsbisb consideredb whenbgenericb drugsb areb substituted b forb
brand-nameb drugs?
A) Bioavailability
B) Criticalb concentration
C) Distribution
D) Half-life
Ans: A
Response:
Bioavailabilityb isb theb portionb of b ab doseb ofbab drugb that b reachesb theb systemicb circulationb a
nd b isb availableb tob act b onb bodybcells.b Bindersb usedbinb ab genericb drugb mayb notbbeb theb same
b asb thoseb used b inb theb brand-
nameb drug.b Therefore,b theb waybtheb bodybbreaksb downbandb usesb theb drugbmayb differ,b whi
chb mayb eliminateb ab substitution.b Criticalb concentrationb isb theb amount b ofbab drugb that b isb n
eeded b tob causeb ab therapeuticb effect.
Distributionb isb theb phaseb of bpharmacokineticsb that binvolvesb thebmovement bof babdrugb tobt
heb body'sb tissues.bA bdrug'sb half-
lifeb isb theb timeb it b takesb forb theb amount bofb drugbtobdecreaseb tob one-half b of b theb peakb level.
CognitivebLevel:b Analysisb Difficult
y:b Difficult
Integrated b Process:b Teaching/learning
5.A bnurseb isb teachingb herb patient b about b theb useb of b over-the-
A) counterb (OTC)b drugs.bWhichb of b theb followingb statementsbbest binformsb thebpatient babout
b theirb safeb use?
B) “OTCb drugsb areb productsb that b areb availableb without b prescriptionb forb self-
b treatment b of b minorb complaints.”
“OTCb drugsb areb considered bmedicationsb andbshould bbebreported bonbabdrugb histor
y.”
Pageb 2
, TestbBank bfor bFocus bOnbNursingbPharmacologyb7thbEditio
n
Chapterb 1:b Introduction b to b Drugs
C) “OTCb drugsb wereb approved basbprescriptionb drugsb butblaterb wereb foundbtobbeb safeb
without b theb need b forb ab prescription.”
D) “OTCb drugsb need btobbebtakenbwithbcaution.bTheyb canb maskb thebsignsb andb sympto
msb of b anb underlyingb diseaseb and b interfereb withb prescriptionb drugb therapy.”
D
Ans: Response:
OTCb drugsb areb considered b medicationsb and bshould bbebreported.bOTCb drugsb areb availab
leb without b ab prescription,b althoughb someb wereb first bapproved basb prescriptionb drugs.bThe
b most b important b teachingb should brelateb tobtheirb safebusebandbthat b OTC b drugsb canb maskb s
ymptomsb of b diseaseb and b interfereb withb prescribed b drugs.
CognitivebLevel:b Knowledgeb Diffic
ulty:b Easy
Integrated b Process:b Nursingb Process
6. Whichb of b theb followingb legislativeb actsb allowed bthebFoodbandbDrugbAdministrationb (
FDA)b tob tightenbcontrolb overb theb qualitybof bdrugsb andbrequired b thatbsafetybandbeffica
cyb standardsb beb established?
A) Pureb Food b and b DrugbAct b of b 1906
B) Federalb Food,b Drug,b and b CosmeticbAct b of b 1938
C) Durhamb HumphreybAmendment b of b 1951
D) Kefauver-HarrisbAct b of b 1962
Ans: D
Response:
Theb Kefauver-
Harrisb Act b wasb theb result b ofbthebuseb ofbtheb1960sb drugb thalidomideb (Thalomid).b Theb pu
blicb concernb led b tob theb legislationb that bgaveb theb FDA bregulatoryb controlb overb testingban
d b evaluatingb of b drugsb andballowed bit b tobset b standardsbforbefficacyband bsafety.b Theb Pureb
Food b and bDrugbActbrequired b labelingb tobeliminateb falseb claims.b Theb Federalb Food,b Dru
g,b and b Cosmeticb Actb gavebthebFDAbthebpowerbtobenforcebstandardsbforbtestingb drugb tox
icityb and b monitoringb labeling.b Theb Durham-
b Humphreyb Amendment b enforced b prescriptionsb forb distribution.
CognitivebLevel:b Applicationb Diffic
ulty:b Moderate
Integrated b Process:b Teaching/learning
7. Abnurseb isb instructingb ab pregnant bpatient bconcerningb thebpotentialb riskb tobherb fetusb f
romb ab pregnancyb categoryb Bb drug.b Theb nurseb would b informb theb patient b that:
A) “Adequateb studiesb inb pregnant bwomenb havebdemonstratedb thereb isbnob riskb tobthebf
etus.”
B) “Animalb studiesb haveb not b demonstratedbabriskb tobthebfetusbbutb thereb havebbeenbn
ob adequateb studiesb inb pregnant b women.”
C) “Animalb studiesb haveb shownb anbadverseb effect bonbtheb fetusb butbtherebareb noba
dequateb studiesb inb pregnant b women.”
D) “Thereb isb evidenceb of b humanb fetalb riskb but bthebpotentialb benefitsbfrombuseb ofbthebd
rugb mayb beb acceptableb despiteb potentialb risks.”
Ans: B
Response:
Categoryb Bb indicatesb that b animalb studiesb haveb not b demonstrated b ab riskb tob theb fetusb but
Pageb 3
b b b b b b b b b b
rch all chapters
b b
Advanced Health Assessment (Walden University)
b b b b
, TestbBank bfor bFocus bOnbNursingbPharmacologyb7thbEditio
n
Chapterb 1:b Introduction b to b Drugs
CognitivebLevel:b Applicationb Diffic
ulty:b Moderate
Integrated b Process:b Nursingb process
1.A b nurseb workingb inb radiologyb administersb iodineb tobabpatient bwhobisb havingb ab comput
erized b axialb tomographyb (CAT)b scan.bAbnurseb workingb onb anb oncologyb unit b administ
ersb chemotherapyb tob patientsb whob havebcancer.b Atb thebPublicb Healthb Department,bab n
urseb administersb ab measles-mumps-rubellab (MMR)b vaccineb tob ab 14-b month-
old b child b asb ab routineb immunization.b Whichb branchb of b pharmacologyb best b describesb t
heb actionsb of b allb threeb nurses?
A) Pharmacoeconomics
B) Pharmacotherapeutics
C) Pharmacodynamics
D) Pharmacokinetics
Ans: B
Response:
Pharmacologyb isb theb studyb of bthebbiologicb effectsbofb chemicals.b Nursesb areb involved b wi
thb clinicalb pharmacologyb orb pharmacotherapeutics,b whichb isb ab branchb of b pharmacology
b that b dealsb withb theb usesbof bdrugsb tobtreat,b prevent,bandbdiagnoseb disease.b Theb nurseb wor
kingb inb radiologyb isb administeringb ab drugb tob helpb diagnoseb ab disease.bTheb nurseb workin
gb onb anb oncologyb unit bisb administeringb ab drugb tob helpbtreat babdisease.b Pharmacoeconomi
csb includesb anyb costsb involved b inb drugb therapy.
Pharmacodynamicsb involvesb howb ab drugbaffectsbtheb body,b and b pharmacokineticsb isb ho
wb theb bodyb actsb onb theb drug.
CognitivebLevel:b Comprehensionb Di
fficulty:b Easy
Integrated b Process:b Nursingb process
2.A b physicianb hasb ordered b intramuscularb injectionsb of b morphine,b ab narcotic,b everyb 4b hour
sb asb needed bforbpainb forb abmotorbvehicleb accident bvictim.bTheb nurseb isb awareb that bthereb is
b ab highb abuseb potentialb forb thisb drug;b therefore,b morphineb isb categorized b asb a:
A) Scheduleb I b drug
B) Scheduleb II b drug
C) Scheduleb III b drug
D) Scheduleb IVb drug
Ans: B
Response:
Narcoticsb suchb asb morphineb areb considered b scheduleb IIb drugsbbecauseb of bthebhighb abuse
b potentialb withb severeb dependenceb liability.b Scheduleb Ibdrugsb haveb highb abusebpotentialb
and b nob accepted bmedicalb use.b Scheduleb III bdrugsb haveb ab lesserb abuseb potentialb thanb sch
eduleb II b drugsbandb anbacceptedbmedicalb use.bScheduleb IVbdrugsbhaveb low babuseb potentia
lb and b limited b dependenceb liability.
CognitivebLevel:b Comprehensionb
Difficulty:b Easy
Integrated b Process:b Communicationb and b documentation
3.A bnurseb workingb forb abdrugb companybisb involved binb phaseb III b drugb evaluationb studies.b
Whichb of b theb followingb might b theb nurseb bebresponsibleb forb duringb thisb stagebof bdrugbde
velopment?
Pageb 1
, TestbBank bfor bFocus bOnbNursingbPharmacologyb7thbEditio
n
Chapterb 1:b Introduction b to b Drugs
A) Workingbwithb animalsb whob areb givenb experimentalb drugs
B) Monitoringb drugb effectsbinbpatientsbwhobarebselected btobparticipateb inbabstudy,bwh
ob haveb theb diseaseb that b theb drugb isb meant b tob treat
C) Collectingb recordsb of b symptomsb that b participantsb experienceb whileb takingb ab dru
gb and b determiningb whetherb theybareb caused bbybthebdiseaseb orb thebdrugb Informing
D) b healthy,b youngb volunteerbparticipantsb ofbpossibleb risksb that bcouldb occurb fromb tak
ingb anb experimentalb drug
Ans: C
Response:
Phaseb III b studiesb involveb useb ofb abdrugb inb ab vast b clinicalb market b whereb patientsb areb aske
d b tob record banybsymptomsb theybexperienceb whileb takingb thebdrugs.b Nursesb maybbeb respo
nsibleb forb helpingb collect b and b analyzeb theb informationb tobbeb sharedb withb theb Food b and b
Drugb Administrationb (FDA).b Usebof banimalsb inb drugb testingb isb donebinb theb preclinicalb tr
ials.b Ab select b groupb of b patientsb whob areb involved binb phaseb II b studiesb participateb inb studi
esb whereb theb participantsb haveb thebdiseaseb theb drugb isb intendedbtobtreat.b Theseb patientsba
reb monitored b closelyb forb drugb effects.bPhaseb Ib studiesb involveb healthyb humanb volunteer
sb whob areb usuallyb paid b forb theirb participation.b Nursesb mayb observeb forb adverseb effectsb a
nd b toxicity.
CognitivebLevel:b Comprehensionb Di
fficulty:b Moderate
Integrated b Process:b Nursingb Process
4. Whichb of b theb followingb conceptsbisb consideredb whenbgenericb drugsb areb substituted b forb
brand-nameb drugs?
A) Bioavailability
B) Criticalb concentration
C) Distribution
D) Half-life
Ans: A
Response:
Bioavailabilityb isb theb portionb of b ab doseb ofbab drugb that b reachesb theb systemicb circulationb a
nd b isb availableb tob act b onb bodybcells.b Bindersb usedbinb ab genericb drugb mayb notbbeb theb same
b asb thoseb used b inb theb brand-
nameb drug.b Therefore,b theb waybtheb bodybbreaksb downbandb usesb theb drugbmayb differ,b whi
chb mayb eliminateb ab substitution.b Criticalb concentrationb isb theb amount b ofbab drugb that b isb n
eeded b tob causeb ab therapeuticb effect.
Distributionb isb theb phaseb of bpharmacokineticsb that binvolvesb thebmovement bof babdrugb tobt
heb body'sb tissues.bA bdrug'sb half-
lifeb isb theb timeb it b takesb forb theb amount bofb drugbtobdecreaseb tob one-half b of b theb peakb level.
CognitivebLevel:b Analysisb Difficult
y:b Difficult
Integrated b Process:b Teaching/learning
5.A bnurseb isb teachingb herb patient b about b theb useb of b over-the-
A) counterb (OTC)b drugs.bWhichb of b theb followingb statementsbbest binformsb thebpatient babout
b theirb safeb use?
B) “OTCb drugsb areb productsb that b areb availableb without b prescriptionb forb self-
b treatment b of b minorb complaints.”
“OTCb drugsb areb considered bmedicationsb andbshould bbebreported bonbabdrugb histor
y.”
Pageb 2
, TestbBank bfor bFocus bOnbNursingbPharmacologyb7thbEditio
n
Chapterb 1:b Introduction b to b Drugs
C) “OTCb drugsb wereb approved basbprescriptionb drugsb butblaterb wereb foundbtobbeb safeb
without b theb need b forb ab prescription.”
D) “OTCb drugsb need btobbebtakenbwithbcaution.bTheyb canb maskb thebsignsb andb sympto
msb of b anb underlyingb diseaseb and b interfereb withb prescriptionb drugb therapy.”
D
Ans: Response:
OTCb drugsb areb considered b medicationsb and bshould bbebreported.bOTCb drugsb areb availab
leb without b ab prescription,b althoughb someb wereb first bapproved basb prescriptionb drugs.bThe
b most b important b teachingb should brelateb tobtheirb safebusebandbthat b OTC b drugsb canb maskb s
ymptomsb of b diseaseb and b interfereb withb prescribed b drugs.
CognitivebLevel:b Knowledgeb Diffic
ulty:b Easy
Integrated b Process:b Nursingb Process
6. Whichb of b theb followingb legislativeb actsb allowed bthebFoodbandbDrugbAdministrationb (
FDA)b tob tightenbcontrolb overb theb qualitybof bdrugsb andbrequired b thatbsafetybandbeffica
cyb standardsb beb established?
A) Pureb Food b and b DrugbAct b of b 1906
B) Federalb Food,b Drug,b and b CosmeticbAct b of b 1938
C) Durhamb HumphreybAmendment b of b 1951
D) Kefauver-HarrisbAct b of b 1962
Ans: D
Response:
Theb Kefauver-
Harrisb Act b wasb theb result b ofbthebuseb ofbtheb1960sb drugb thalidomideb (Thalomid).b Theb pu
blicb concernb led b tob theb legislationb that bgaveb theb FDA bregulatoryb controlb overb testingban
d b evaluatingb of b drugsb andballowed bit b tobset b standardsbforbefficacyband bsafety.b Theb Pureb
Food b and bDrugbActbrequired b labelingb tobeliminateb falseb claims.b Theb Federalb Food,b Dru
g,b and b Cosmeticb Actb gavebthebFDAbthebpowerbtobenforcebstandardsbforbtestingb drugb tox
icityb and b monitoringb labeling.b Theb Durham-
b Humphreyb Amendment b enforced b prescriptionsb forb distribution.
CognitivebLevel:b Applicationb Diffic
ulty:b Moderate
Integrated b Process:b Teaching/learning
7. Abnurseb isb instructingb ab pregnant bpatient bconcerningb thebpotentialb riskb tobherb fetusb f
romb ab pregnancyb categoryb Bb drug.b Theb nurseb would b informb theb patient b that:
A) “Adequateb studiesb inb pregnant bwomenb havebdemonstratedb thereb isbnob riskb tobthebf
etus.”
B) “Animalb studiesb haveb not b demonstratedbabriskb tobthebfetusbbutb thereb havebbeenbn
ob adequateb studiesb inb pregnant b women.”
C) “Animalb studiesb haveb shownb anbadverseb effect bonbtheb fetusb butbtherebareb noba
dequateb studiesb inb pregnant b women.”
D) “Thereb isb evidenceb of b humanb fetalb riskb but bthebpotentialb benefitsbfrombuseb ofbthebd
rugb mayb beb acceptableb despiteb potentialb risks.”
Ans: B
Response:
Categoryb Bb indicatesb that b animalb studiesb haveb not b demonstrated b ab riskb tob theb fetusb but
Pageb 3
